IN THIS ISSUE (starts on next page)
In Brief: Khedezla — A New Brand of Desvenlafaxine ........................p 4

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769
IN BRIEF

*Khedezla* – A New Brand of Desvenlafaxine

The FDA has approved the marketing of another extended-release brand-name formulation of the serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (*Khedezla* – Par/Osmotica) for treatment of depression. It is the third extended-release formulation of desvenlafaxine to become available in the US. *Khedezla* was approved using a 505(b)(2) application, a new drug application (NDA) that relies upon the FDA's findings of safety and/or effectiveness for a previously approved drug.

Table 1. Desvenlafaxine Products

<table>
<thead>
<tr>
<th>Drug</th>
<th>Usual Adult Dosage</th>
<th>Cost 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desvenlafaxine succinate² – Pristiq (Pfizer)</td>
<td>50 mg once/d</td>
<td>$177.00</td>
</tr>
<tr>
<td>Desvenlafaxine base² – (Ranbaxy/Alembic)</td>
<td>50 mg once/d</td>
<td>139.00</td>
</tr>
<tr>
<td>Khedezla (Par/Osmotica)</td>
<td></td>
<td>134.00</td>
</tr>
</tbody>
</table>

1. Approximate wholesale acquisition cost (WAC) for 30 days' treatment at the usual daily dosage. Source: Analy$ource® Monthly (Selected from FDB MedKnowledge™) December 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.

2. Extended- or delayed-release.

*Khedezla* does not appear to offer any advantage over the other extended-release formulations of desvenlafaxine. There is no evidence that any formulation of desvenlafaxine is more effective for treatment of depression than other SNRIs or any SSRI, which are available in less expensive generic formulations.¹

Coming Soon in The Medical Letter:
Omacetaxine Mepesuccinate (Synribo) for CML
Sofosbuvir (Sovaldi) for Chronic Hepatitis C
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis

Coming Soon in Treatment Guidelines:
Drugs for HIV Infection
Treatment of Atrial Fibrillation